{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:10:45Z","timestamp":1760267445602},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ejps.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T02:00:41Z","timestamp":1470276041000},"page":"82-87","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Biopharmaceutic classification of drugs revisited"],"prefix":"10.1016","volume":"95","author":[{"given":"Chrysa","family":"Daousani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panos","family":"Macheras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.08.001_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.010","article-title":"Is the full potential of the biopharmaceutics classification system reached?","volume":"57","author":"Bergstr\u00f6m","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2013.10.015","article-title":"Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs","volume":"57","author":"Bergstr\u00f6m","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2174\/138920008786485155","article-title":"Using measured pKa, log P and solubility to investigate supersaturation and predict BCS Class","volume":"9","author":"Box","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2016.08.001_bb0025","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.2042-7158.2010.01226.x","article-title":"Supersaturated dissolution data and their interpretation: the TPGS- carbamazepine model case","volume":"63","author":"Charkoftaki","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2016.08.001_bb0035","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1007\/s11095-012-0815-4","article-title":"Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility and dose-dependent BCS","volume":"29","author":"Charkoftaki","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0040","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/aic.15017","article-title":"New frames of reference for mapping drugs in the four classes of the BCS and BDDCS into regions with clear boundaries","volume":"61","author":"Chatzizacharia","year":"2015","journal-title":"Am. Inst. Chem. Eng. J."},{"key":"10.1016\/j.ejps.2016.08.001_bb0045","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0050","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.21502","article-title":"Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states","volume":"98","author":"Clarysse","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/mp1001747","article-title":"Impact of biopharmaceutics classification system-based biowaivers","volume":"7","author":"Cook","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0060","first-page":"107","article-title":"Approximate solution of nonlinear fractional order biochemical reaction model by multistage new iterative method","volume":"5","author":"Damarla","year":"2014","journal-title":"J. Fractional Calc. Appl."},{"key":"10.1016\/j.ejps.2016.08.001_bb0065","first-page":"606","article-title":"Scientific considerations concerning the EMA change in the definition of \u201cdose\u201d of the BCS-based biowaiver guideline and implications for bioequivalence intern","volume":"478","author":"Daousani","year":"2015","journal-title":"J. Pharmacogn."},{"key":"10.1016\/j.ejps.2016.08.001_bb0070","first-page":"1","article-title":"Fractional kinetics in multi-compartmental systems","volume":"37","author":"Dokoumetzidis","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2016.08.001_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.07.011","article-title":"A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system","volume":"321","author":"Dokoumetzidis","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0080","first-page":"165","article-title":"Fractional kinetics in drug absorption and disposition processes","volume":"36","author":"Dokoumetzidis","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2016.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s11095-011-0370-4","article-title":"The changing face of the rate concept in biopharmaceutical sciences: from classical to fractal and finally to fractional","volume":"28","author":"Dokoumetzidis","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jps.2600750202","article-title":"Mixing-tank model for predicting dissolution rate control or oral absorption","volume":"75","author":"Dressman","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jps.2600740523","article-title":"Absorption potential: estimating the fraction absorbed for orally administered compounds","volume":"74","author":"Dressman","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0100","series-title":"Guideline on the Investigation of Bioequivalence. CPMP\/EWP\/QWP\/1401\/98 Rev.1","author":"EMA","year":"2010"},{"key":"10.1016\/j.ejps.2016.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/mp100049m","article-title":"Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media","volume":"7","author":"Fagerberg","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0110","series-title":"Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System","author":"FDA","year":"2000"},{"key":"10.1016\/j.ejps.2016.08.001_bb0115","series-title":"Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Draft Guidance","author":"FDA","year":"2015"},{"key":"10.1016\/j.ejps.2016.08.001_bb0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10928-013-9340-2","article-title":"How to avoid unbounded drug accumulation with fractional pharmacokinetics","volume":"40","author":"Hennion","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1\u20133","key":"10.1016\/j.ejps.2016.08.001_bb0125","first-page":"75","article-title":"Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract","volume":"46","author":"Horter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ejps.2016.08.001_bb0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.2042-7158.1991.tb06688.x","article-title":"Unusual solubility behaviour of cyclosporin A in aqueous media","volume":"43","author":"Ismailos","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2016.08.001_bb0135","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1023\/A:1018918402237","article-title":"A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts","volume":"16","author":"Kalampokis","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1018874913372","article-title":"A heterogeneous tube model for the study of small intestinal transit flow","volume":"16","author":"Kalampokis","year":"1999","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2016.08.001_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-4682-9-39","article-title":"Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products","volume":"9","author":"Kim","year":"2012","journal-title":"Theor. Biol. Med. Model."},{"key":"10.1016\/j.ejps.2016.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1126\/science.241.4873.1620","article-title":"Fractal reaction kinetics","volume":"241","author":"Kopelman","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ejps.2016.08.001_bb0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejps.2010.06.015","article-title":"Power law IVIVC: an application of fractional kinetics for drug release and absorption","volume":"41","author":"Kytariolos","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1023\/A:1012183313218","article-title":"Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity?","volume":"14","author":"Macheras","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0175","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1007596709657","article-title":"On the heterogeneity of drug dissolution and release","volume":"17","author":"Macheras","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0180","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/jps.23534","article-title":"Keeping a critical eye on the science and the regulation of oral drug absorption: a review","volume":"102","author":"Macheras","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2014.01.022","article-title":"A non-binary biopharmaceutical classification of drugs: the AB\u0393 system","volume":"464","author":"Macheras","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1016201929304","article-title":"Carrier-mediated transport can obey fractal kinetics","volume":"12","author":"Macheras","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0195","series-title":"Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches","first-page":"4835","author":"Macheras","year":"2016"},{"key":"10.1016\/j.ejps.2016.08.001_bb0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/bdd.2510100106","article-title":"Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept","volume":"10","author":"Macheras","year":"1989","journal-title":"Biopharm. Drug Dispos."},{"issue":"4","key":"10.1016\/j.ejps.2016.08.001_bb0205","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1208\/s12249-009-9346-7","article-title":"Effect of cyclodextrin complexation on the aqueous solubility and solubility\/dose ratio of praziquantel","volume":"10","author":"Maragos","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2016.08.001_bb0210","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0215","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1023\/A:1018947113238","article-title":"Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model","volume":"10","author":"Oh","year":"1993","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejps.2016.08.001_bb0220","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1208\/s12248-015-9758-0","article-title":"Translating human effective jejunal intestinal permeability to surface-dependent intrinsic permeability: a pragmatic method for a more mechanistic prediction of regional oral drug absorption","volume":"17","author":"Olivares-Morales","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2016.08.001_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2008.05.021","article-title":"Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples","volume":"361","author":"Papadopoulou","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb9000","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1211\/jpp.58.8.0009","article-title":"Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum","volume":"58","author":"Perez de la Cruz Moreno","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2016.08.001_bb0235","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijpharm.2013.08.087","article-title":"On the ubiquitous presence of fractals and fractal concepts in pharmaceutical sciences: a review","volume":"456","author":"Pippa","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2016.08.001_bb0240","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0245","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1023\/B:PHAM.0000041450.25106.c8","article-title":"Identification of biowaivers among Class II drugs: theoretical justification and practical examples","volume":"21","author":"Rinaki","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0250","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1023\/B:PHAM.0000008037.57884.11","article-title":"Quantitative biopharmaceutics classification system: the central role of dose\/solubility ratio","volume":"20","author":"Rinaki","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0255","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.08.001_bb0260","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1007\/s11095-015-1675-5","article-title":"Unstirred water layers and the kinetics of organic cation transport","volume":"32","author":"Shibayama","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0265","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1023\/A:1015892621261","article-title":"Predicting fraction dose absorbed in humans using a macroscopic mass balance approach","volume":"8","author":"Sinko","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0270","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/mp500834v","article-title":"Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data","volume":"12","author":"Sj\u00f6gren","year":"2015","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.ejps.2016.08.001_bb0275","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1002\/jps.24391","article-title":"Rate- and extent-limiting factors of oral drug absorption: theory and applications","volume":"104","author":"Sugano","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.08.001_bb0280","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/mp2004912","article-title":"pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery","volume":"9","author":"Varma","year":"2012","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.ejps.2016.08.001_bb0285","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00007890-199510150-00005","article-title":"Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period","volume":"60","author":"Wahlberg","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.ejps.2016.08.001_bb0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2010.04.044","article-title":"The transit of dosage forms through the colon","volume":"395","author":"Wilson","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0005-2736(77)90375-3","article-title":"Correction of the apparent Michaelis constant, biased by an unstirred layer, if a passive transport component is present","volume":"464","author":"Winne","year":"1977","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2016.08.001_bb0300","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0305","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-006-9000-y","article-title":"A \u2018rule of unity\u2019 for human intestinal absorption","volume":"23","author":"Yalkowsky","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0310","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/B:PHAM.0000016242.48642.71","article-title":"The \u201chigh solubility\u201d definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs","volume":"21","author":"Yazdanian","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.08.001_bb0315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5173(98)00174-4","article-title":"Characterization of small intestinal transit time distribution in humans","volume":"171","author":"Yu","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental transit and dispersion model analysis of small intestinal transit flow in humans","volume":"140","author":"Yu","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.08.001_bb0325","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T10:51:28Z","timestamp":1536490288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716302901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":64,"alternative-id":["S0928098716302901"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.08.001","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biopharmaceutic classification of drugs revisited","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}